FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda and have given "Apply" recommendation to Healthcare Global IPO. recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 2 | 0 | 0 | 1 | 0 |
% | 66.67 | 0.00 | 0.00 | 33.33 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Apply | |
Avoid | ||
Apply |
The Captial Market (CapitalMarket.com) rating for Healthcare Global IPO is 40. Their analysis recommends Avoid, however active risk seekers can try for the IPO.
Reviewer | Rating Score | Rating |
---|---|---|
Capital Market | 40 | Avoid, however active risk seekers can try |
[Dilip Davda]
Although the company’s performance has been in negative zone, unique model of Cancer and Fertility treatment under HCG and Milann brands are expected to generate positive earnings in next two to three years. Long term investors may consider investment for adding value on their investment.
Read detail review...Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|